Persistent immune activation in chronic HIV infection: do any interventions work?
about
Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapyThe evolving scenario of non-AIDS-defining cancers: challenges and opportunities of careDisease-promoting effects of type I interferons in viral, bacterial, and coinfectionsThe end of AIDS: HIV infection as a chronic diseaseImmune Activation Influences SAMHD1 Expression and Vpx-mediated SAMHD1 Degradation during Chronic HIV-1 InfectionCommunicable and non-communicable diseases: connections, synergies and benefits of integrating care.Plasma IP-10 Concentrations Correlate Positively with Viraemia and Inversely with CD4 Counts in Untreated HIV InfectionFrequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.Microbiota and Probiotics in Health and HIV Infection.The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages.Chronic HIV disease and activation of the coagulation systemKSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection.New insights into type I interferon and the immunopathogenesis of persistent viral infections.Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy.Distortion of memory Vδ2 γδ T cells contributes to immune dysfunction in chronic HIV infection.Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput AssayIntegrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trialThe association between alcohol use and cardiovascular disease among people living with HIV: a systematic review.Chronic alcohol increases CD8+ T-cell immunosenescence in simian immunodeficiency virus-infected rhesus macaques.The Selective Serotonin Reuptake Inhibitor Citalopram Decreases Human Immunodeficiency Virus Receptor and Coreceptor Expression in Immune Cells.HIV-infected adolescent, young adult and pregnant smokers: important targets for effective tobacco control programs.Altering cell death pathways as an approach to cure HIV infection.Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Diagnosis and management of lymphomas and other cancers in HIV-infected patients.Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications.Non-linear resistance training reduces inflammatory biomarkers in persons living with HIV: A randomized controlled trial.Acupuncture to Reduce HIV-Associated Inflammation.Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.High immune activation and abnormal expression of cytokines contribute to death of SHIV89.6-infected Chinese rhesus macaques.Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety.Short communication: Apoptosis pathways in HIV-1-infected patients before and after highly active antiretroviral therapy: relevance to immune recovery.Deregulated MicroRNA-21 Expression in Monocytes from HIV-Infected Patients Contributes to Elevated IP-10 Secretion in HIV Infection.
P2860
Q26797749-2955F8C4-5168-415F-858A-00C7041547F2Q26991549-4C5FC483-143D-4EBB-9661-D9CA27EA5F04Q28082841-0E671C40-66E2-455A-B47A-33ACD9796841Q28300749-CC58E21E-1404-4BA4-B498-BAA5E63F2B43Q28589591-A02D2C28-C63B-4003-A279-7782E9E45F6BQ30387611-C4A60F48-C338-4640-82A7-31F96FC9ED88Q33668482-702C288C-085F-40E0-ADFF-5F820AA52BC3Q33707759-1C19059D-CB65-4E38-8DC5-9823AFED05C2Q33852108-95BBB803-EC67-4EA4-92BE-5ED844A69168Q33884876-0E8230D5-2D54-42D1-9996-947AB42036ACQ34342368-9D0F3DE9-D36F-46EA-926E-534A8D8AF67DQ34417383-6AB86473-2FAA-4D84-83DE-4A0AEF6B247CQ35018886-BCF1B215-41EC-4CE8-8DAE-3A6920344F10Q35082803-3887F3C1-8468-48B9-B9B8-67FEAA65940BQ35648751-AEA671D2-C7D1-421F-8562-33F32463EF9CQ35904816-4BB84B91-66E6-425F-9322-6474289045ADQ36015621-66183D4A-62C7-443B-8007-DD70221CC03FQ36085070-58AFCFD1-C09C-483E-8255-93BE29250569Q36217715-BC9A8B22-A93E-4991-8F61-4EFFD8074900Q36238363-AC0F4B43-F9AB-41FE-8C92-C0100D256282Q36339858-23F17DBF-4834-4B66-94FC-AEE26AF1A49AQ36389888-8CC52B75-8076-4BB9-869D-1B86BD59B23DQ36404961-8CA429EF-8761-4642-BD77-FD3F06853153Q36889342-83EFB305-9BE3-4927-A796-5B5031E71DF1Q37030799-CD685D15-87C8-4234-8ACB-917E01FE993EQ37062057-4D9C2822-3CE1-4BFF-9930-A7ED2EB38889Q37122279-F858A8A6-B093-4B80-918E-3DE6E5DBF085Q38194845-B1ADBDEF-48AE-4854-97E3-3E93BAFE2907Q38530430-84472E6C-5107-4F51-90EE-0FC2148F4D6FQ38887659-8321CB00-15FD-4563-8768-2DF30F5245AEQ39110897-378489C1-25C6-470A-8F09-D2FF938C407EQ39395758-59ED9A57-0EA0-4D08-B209-0B941A37D561Q39622641-D97270C3-BC57-4175-B700-27B3E1C52E65Q39683044-6B915343-B01D-4673-96D4-611AFA8F89EEQ40536799-5C2777B6-8D9B-4393-9EB5-31CF17ACB62DQ40643518-2B61C991-6B60-4FA6-83C4-C2A5DC92BE37Q41189354-DE065CC0-E173-4B44-87AC-7DCEF95686A1Q41333604-6C00FC96-6D61-4CDF-8AAE-4B2C791EE83FQ41668051-2720BA17-58F2-49A5-9125-A36E7DA53EA1Q41684137-D005C6A3-114F-4DD3-9482-9EF547E4C4AC
P2860
Persistent immune activation in chronic HIV infection: do any interventions work?
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Persistent immune activation in chronic HIV infection: do any interventions work?
@ast
Persistent immune activation in chronic HIV infection: do any interventions work?
@en
Persistent immune activation in chronic HIV infection: do any interventions work?
@nl
type
label
Persistent immune activation in chronic HIV infection: do any interventions work?
@ast
Persistent immune activation in chronic HIV infection: do any interventions work?
@en
Persistent immune activation in chronic HIV infection: do any interventions work?
@nl
prefLabel
Persistent immune activation in chronic HIV infection: do any interventions work?
@ast
Persistent immune activation in chronic HIV infection: do any interventions work?
@en
Persistent immune activation in chronic HIV infection: do any interventions work?
@nl
P2860
P50
P1433
P1476
Persistent immune activation in chronic HIV infection: do any interventions work?
@en
P2093
Gabriela Khoury
Paul U Cameron
P2860
P304
P356
10.1097/QAD.0B013E32835ECB8B
P407
P577
2013-05-01T00:00:00Z